Cinacalcet (Sensipar): Teva sued innovator for process patent infringement

Teva has filed patent infringement lawsuit against Innovator Company Amgen w.r.t Cinacalcet process patent infringement in Distric court for Eastern district of Pennsylvania. Generic pharma giant Teva got following process patent:

US7449603 (assignee: Teva, Date of Grant: November 11, 2008): Which covers process and intermediates for the synthesis of Cincalcet

Earlier, innovator sued Barr (Now, subsidiary of Teva) for filing Para IV on Cinacalcet (Sensipar) 30, 60 and 90 mg tablets in March, 2008 as reported by us Here . Subsequently, innovator sued Teva and Barr in Delaware district court in July, 2008.

Now, it will be interesting to monitor counter litigation strategy of Teva against innovator.

Also, Teva has asserted it’s API process patents on Carvedilol (Coreg) like US7,056,942, US6,710,184, US6,699,997, and US7,126,008 against various generic players and later on settled with some players like Ranbaxy Laboratories, Dr Reddy's Laboratories and USV Ltd , Glenmark (as reported by us on this product Here ) and recently with Cadilla . The product patent on Carvedilol has already expired but API process patents of Teva are blocking for other generic players.